GFM
ORIC icon

GF Fund Management’s Oric Pharmaceuticals ORIC Stock Holding History

GF Fund Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.6K Buy
2,176
+263
+14% +$2.99K ﹤0.01% 463
2025
Q4 		$15.6K Sell
1,913
-177
-8% -$2.04K ﹤0.01% 533
2025
Q3 		$25.1K Buy
2,090
+283
+16% +$2.98K ﹤0.01% 462
2025
Q2 		$18.3K Hold
1,807
– – ﹤0.01% 509
2025
Q1 		$10.1K Buy
1,807
+325
+22% +$2.84K ﹤0.01% 563
2024
Q4 		$12K Buy
+1,482
New +$13.6K ﹤0.01% 522

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

GF Fund Management's ORIC Position: Q1 2026 in Review

GF Fund Management increased its Oric Pharmaceuticals (ORIC) stake by 14% in Q1 2026, buying an estimated $2.99K and bringing the position to 2,176 shares worth $27.6K. The position accounts for ﹤0.01% of the portfolio, ranked #463.

GF Fund Management first reported a position in ORIC in Q4 2024 and has held it in 6 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • GF Fund Management held 2,176 shares of Oric Pharmaceuticals worth $27.6K as of Q1 2026.
  • GF Fund Management bought 263 Oric Pharmaceuticals shares in Q1 2026, an estimated $2.99K.
  • Oric Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #463 holding.
  • GF Fund Management first reported a position in Oric Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.